Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 10:43 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 1,163 matching trials from the live ClinicalTrials.gov search.
Completed Not applicable Interventional Accepts healthy volunteers Results available

Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT)

NCT00915954
Conditions
Acromegaly, Type 2 Diabetes Mellitus
Interventions
Oral Glucose Tolerance Test, Subcutaneous administration of recombinant human IGF-1, Placebo
Diagnostic Test
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Hepatitis C
Interventions
Alisporivir, Peginterferon alfa-2a, Ribavirin, Placebo
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
18
States / cities
San Diego, California • Ventura, California • Bradenton, Florida + 13 more
Conditions
Atopic Dermatitis
Interventions
BxC-I17e (primed iMSC derived Extracellular vesicles(EV)), Placebo
Drug
Lead sponsor
Brexogen Inc.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
North Little Rock, Arkansas • Camp Hill, Pennsylvania • Philadelphia, Pennsylvania
Conditions
Granulomatosis With Polyangiitis (Wegener's), Granulomatosis With Polyangiitis, Wegener's Granulomatosis, ANCA-Associated Vasculitis
Interventions
Abatacept, placebo
Drug
Lead sponsor
University of South Florida
Other
Eligibility
15 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
10
States / cities
Los Angeles, California • Tampa, Florida • Kansas City, Kansas + 7 more
Conditions
Hereditary Angioedema (HAE)
Interventions
ecallantide, Phosphate Buffer Saline (PBS), pH 7.0
Drug
Lead sponsor
Shire
Industry
Eligibility
10 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
42
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Berkeley, California + 38 more
Conditions
Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
Interventions
TransCon PTH, Placebo for TransCon PTH
Combination Product
Lead sponsor
Ascendis Pharma A/S
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
5
States / cities
Chicago, Illinois • Rochester, Minnesota • Great Neck, New York + 2 more
Conditions
Plaque Psoriasis, Scalp Psoriasis
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
79
States / cities
Birmingham, Alabama • Beverly Hills, California • Encinitas, California + 67 more
Withdrawn Phase 1 Interventional Accepts healthy volunteers

TDENV PIV and LAV Dengue Prime-boost Strategy Using AS03B Adjuvant

NCT03110952
Conditions
Dengue
Interventions
TDENV-PIV, TDENV-F17, Placebo
Biological · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 39 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Syracuse, New York
Conditions
Hidradenitis Suppurativa (HS)
Interventions
Placebo, Adalimumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
9
States / cities
Beverly Hills, California • Encino, California • Irvine, California + 6 more
Conditions
Hyperlipidemia
Interventions
Evolocumab, Ezetimibe, Placebo to Evolocumab, Placebo to Ezetimibe
Biological · Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
615 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
47
States / cities
Birmingham, Alabama • Chandler, Arizona • Little Rock, Arkansas + 40 more
Conditions
Diabetes Mellitus Type 2
Interventions
BMS-986036, Placebo (Matching with BMS-986036)
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
Not listed
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Little Rock, Arkansas • Anaheim, California • Los Angeles, California + 6 more
Conditions
Osteoporosis
Interventions
Teriparatide, Alendronate, Calcium, Vitamin D, Placebo-Oral, Placebo-SC
Drug · Dietary Supplement
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years to 85 Years · Female only
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
15
States / cities
Mobile, Alabama • Tustin, California • Lakewood, Colorado + 12 more
Conditions
Liver Fibrosis Due to NASH
Interventions
Placebo, SIM
Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
41
States / cities
Phoenix, Arizona • Coronado, California • San Diego, California + 34 more
Conditions
Asthma
Interventions
Lunsekimig, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
685 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
48
States / cities
Scottsdale, Arizona • Yuma, Arizona • Lancaster, California + 41 more
Conditions
Hypertriglyceridemia, Atherosclerotic Cardiovascular Disease, Severe Hypertriglyceridemia
Interventions
Olezarsen, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
21
States / cities
Lincoln, California • Montclair, California • Boca Raton, Florida + 17 more
Conditions
Dermatomyositis
Interventions
IMO-8400 Dose Group 1, IMO-8400 Dose Group 2, Placebo
Drug
Lead sponsor
Idera Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
17
States / cities
Birmingham, Alabama • Phoenix, Arizona • Irvine, California + 14 more
Conditions
Type 2 Diabetes, Chronic Inflammation, Intestinal Permeability
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
ST-elevation Myocardial Infarction (STEMI)
Interventions
zalunfiban, Placebo
Drug
Lead sponsor
CeleCor Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
2,463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
5
States / cities
Anchorage, Alaska • Royal Oak, Michigan • St Louis, Missouri + 2 more
Conditions
Plaque Psoriasis
Interventions
MEDI-507, Placebo
Drug · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
36
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Fresno, California + 29 more
Conditions
HCV Infection
Interventions
placebo, ANA598, Peginterferon, Ribavirin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
20
States / cities
Anaheim, California • Los Angeles, California • San Clemente, California + 17 more
Conditions
Acute Gouty Arthritis
Interventions
Anakinra 100 mg, Triamcinolone Acetonide 40 mg, Placebo to Anakinra 100 mg, Placebo to Triamcinolone Acetonide 40 mg
Drug
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
37
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Mobile, Alabama + 32 more
Conditions
Idiopathic Intracranial Hypertension (IIH), Pseudotumor Cerebri, Papilledema
Interventions
Tirzepatide, Placebo, Acetazolamide
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Psoriatic Arthritis
Interventions
Placebo, Risankizumab
Biological
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
964 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
59
States / cities
Anniston, Alabama • Peoria, Arizona • Phoenix, Arizona + 53 more
Conditions
Allergy, Peanut
Interventions
ligelizumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 55 Years
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
29
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 23 more